Context.—: Primary breast carcinomas constitute a divergent group of neoplasms. The classification of breast tumors has been evolving. Recent advances in molecular genetic techniques have enhanced our understanding of these diseases. Integration of state-of-the-art knowledge from research and practice has resulted in the recognition of novel entities as primary carcinomas of the breast with therapeutic and prognostic significance.
Objective.—: To provide an overview of current concepts in the classification and diagnosis of selective salivary-type carcinomas of the breast, focusing on their salient histologic and immunophenotypic characteristics and recent molecular genetic advancements.
Data Sources.—: Data were obtained from review of pertinent English-language literature and firsthand experience of the authors as practicing breast pathologists.
Conclusions.—: The cutting-edge knowledge has led us to further understand a growing number of uncommon types of breast carcinoma that demonstrate morphologic and immunophenotypic resemblance to those more frequently encountered in other organ systems, particularly salivary glands. Some of them also harbor identical molecular genetic alterations to those in their salivary gland counterparts. Yet they typically have diverse prognostic outcomes, thus warranting different clinical management. Accurate diagnosis of these tumors necessitates recognition of salient histologic features and judicious assessment of ancillary studies in the pursuit of precision medicine.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5858/arpa.2022-0028-RA | DOI Listing |
J Immunother Cancer
January 2025
National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an, Shaanxi, China
Background: Clear cell renal cell carcinoma (ccRCC) is the most common histologic type of RCC. However, the spatial and functional heterogeneity of immunosuppressive cells and the mechanisms by which their interactions promote immunosuppression in the ccRCC have not been thoroughly investigated.
Methods: To further investigate the cellular and regional heterogeneity of ccRCC, we analyzed single-cell and spatial transcriptome RNA sequencing data from four patients, which were obtained from samples from multiple regions, including the tumor core, tumor-normal interface, and distal normal tissue.
Food Chem Toxicol
January 2025
Zoology Department, Faculty of Science, Al-Azhar University, 71524 Assuit, Egypt.
This study aimed to define the antitumor effect of ethanolic extract of Pistacia vera leaves (PEE) toward breast cancer both in vitro and in vivo using dimethyl-benz(a)anthracene (DMBA)-induced breast tumor in adult female rats. PEE showed a potent antioxidant effect toward both DPPH (1,1-diphenyl-2-picrylhydrazyl) and ABTS (2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) radicals with IC values of 72.6 and 107.
View Article and Find Full Text PDFESMO Open
January 2025
Department of Medicine and DRCI, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France.
Background: Paraneoplastic inflammatory syndrome (PIS) with fever and biological inflammation is a rare but severe condition often caused by the systemic production of interleukin 6 (IL-6) by cancer cells. We report on the efficacy of tocilizumab, an anti-IL-6 receptor antibody, in 35 patients with severe PIS.
Patients And Methods: All 35 patients with solid cancers (sarcomas, lung carcinoma, and breast carcinoma) diagnosed with a PIS from 2019 to 2024 treated with tocilizumab were analyzed in this single-center study (health authorities' approval R201-004-478).
Breast
January 2025
Department of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. Electronic address:
Purpose: To investigate the clinical value of Clinical Treatment Score Post-5 Years (CTS5) to predict the survival benefits of postmastectomy radiotherapy (PMRT) of patients with T1-2N1 luminal breast cancer (BC).
Methods: Patients who were diagnosed with T1-2N1 luminal BC between 2010 and 2015 were included in the Surveillance, Epidemiology, and End Results database. The chi-square test, binomial logistic regression, Kaplan-Meier analysis, and multivariable Cox proportional hazard model were used for statistical analyses.
J Drug Target
January 2025
Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka, 575018, India.
Breast cancer (BC) is a substantial reason for cancer-related mortality among women across the globe. Anastrozole (ANS) is an effective orally administered hormonal therapy for estrogen+ (ER+) BC treatment. However, several side effects and pharmacokinetic limitations restricted its uses in BC treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!